AVRO - AVROBIOAbout Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
| Previous Close | $11.09 | Open | $11.13 |
| Volume | 42.9K | Market Cap | 430.79M |
| Yield | Last Dividend |
| AVROBIO Reports Fourth Quarter and Fisca... | 03/18/21 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people... | |
| AVROBIO Earnings Report: Here???s what t... | 03/15/21 |
| AVROBIO announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by??? | |
| AVROBIO Receives Orphan Drug Designation... | 03/01/21 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people... | |
| AVROBIO to Present at Three Upcoming Inv... | 02/25/21 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people... | |
| Gene therapy leaders may need M&A to sol... | 02/24/21 |
| Summary List Placement Reports of patients deaths, cancer cases, and other potential safety issues in the gene therapy field have made some investors ... | |
| Why Moderna, Avrobio, And More Are Movin... | 02/08/21 |
| Moderna (NASDAQ: MRNA ) shares are trading higher amid South ??? Full story available on Benzinga.com | |
| AVROBIO Announces 100% Kidney Substrate ... | 02/08/21 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people... | |
| AVROBIO Announces Inducement Grants Unde... | 02/05/21 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people... | |
| AVROBIO Announces Multiple Clinical Data... | 02/01/21 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people... | |
| AVROBIO to Present at the Cowen 2021 Gen... | 01/22/21 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq:AVRO), a leading clinical-stage gene therapy company with a mission to free people ... | |
| AVROBIO Announces the Appointment of Dia... | 01/19/21 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people... | |
| AVROBIO to Present at the ICR Conference... | 01/08/21 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company with a mission to free people... | |
| AVROBIO Announces Inducement Grant Under... | 12/04/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people... | |
| AVROBIO Announces Closing of Underwritte... | 11/24/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company, today announced the closing ... | |
| FY2024 Earnings Forecast for AVROBIO, In... | 11/20/20 |
| AVROBIO, Inc. (NASDAQ:AVRO) ??? Analysts at SVB Leerink raised their FY2024 earnings estimates for AVROBIO in a research note issued to investors on W... | |
| AVROBIO Announces Pricing of Underwritte... | 11/19/20 |
| AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company, today announced the pricing of an underwritten public offering of 5,000,0 | |
| AVROBIO Announces Proposed Public Offeri... | 11/19/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company, today announced that it inten... | |
| AVROBIO Announces New Positive Clinical ... | 11/17/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people... | |
| AVROBIO Announces Inducement Grants Unde... | 11/06/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people... | |
| AVROBIO Reports Third Quarter 2020 Finan... | 11/05/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people... | |
| Fabry Disease Drug Market 2020 Industry ... | 11/03/20 |
| This Fabry Disease Drug Market research report is a great store to acquire current as well as upcoming technical and financial details of the industry... | |
| AVROBIO Receives Orphan Drug Designation... | 10/29/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people... | |
| AVROBIO to Share Clinical and Pipeline U... | 10/26/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people... | |
| Reviewing AVROBIO (NASDAQ:AVRO) & I-Mab ... | 10/23/20 |
| AVROBIO (NASDAQ:AVRO) and I-Mab (NASDAQ:BDTX) are both small-cap medical companies, but which is the superior business? We will contrast the two busin... | |
| AVROBIO Appoints Dr. Gail Farfel to its ... | 10/21/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people... | |
| AVROBIO Receives Orphan Drug Designation... | 09/28/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people... | |
| AVROBIO to Present at Three Upcoming Inv... | 09/03/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people... | |
| AVROBIO : at the 2020 Wedbush PacGrow He... | 08/12/20 |
| Company Presentation Wedbush PacGrow Healthcare Virtual Conference August 2020 Disclaimer ??? | August 12, 2020 | |
| AVROBIO : Investor Presentation August 2... | 08/06/20 |
| Company Presentation August 2020 Disclaimer This??? | August 6, 2020 | |
| AVROBIO Reports Second Quarter 2020 Fina... | 08/06/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq:AVRO), a leading clinical-stage gene therapy company with a mission to free people ... | |
| Strong Buy rating | 03/09/21 |
| Barclays initiates coverage with Overweight rating and announces Price Target of $23.00 | |
| Hold rating | 03/02/21 |
| Stifel initiates coverage with Hold rating and announces Price Target of $14.00 | |
| Date | 2021-03-18 (BMO) | Est. (EPS/Rev.) | ($0.90)/ 0 |
| Actual (EPS/Rev.) | $-0.73/ | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
